DALLAS, April 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. announced today that it has continued to expand the number of clinical trial sites for its on-going Phase 2 trial of ProLindac in patients with recurrent platinum-sensitive ovarian cancer. The number of sites opened has now reached 11, up from two initial sites when the trial was commenced last year. The additional sites allow for the potential of more rapid patient accrual.
“We are pleased with the increase in hospitals that are interested in participating in our ProLindac ovarian cancer trial,” said Stephen R. Seiler, Access’ Chief Executive Officer. “The expanded number of sites also gives us the advantage of being able to draw from a larger potential patient population for trial enrolment.”
ProLindac, is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes ProLindac’s unique molecular design potentially could eliminate some of the toxic neurological side effects seen in the currently marketed DACH platinum, oxaliplatin, which has sales in excess of $2 billion. In a Phase 1 clinical study, at least five times more DACH platinum could be administered to patients with ProLindac(TM) than oxaliplatin before the onset of toxicity.
About Access
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access’ products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success, our ability to expand our clinical trial sites and enroll additional patients and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company’s Annual Report on Form 10-KSB for the year ended December 31, 2006 and other reports filed by us with the Securities and Exchange Commission.
Access Pharmaceuticals, Inc.
CONTACT: Stephen B. Thompson, Vice President, Chief Financial Officer ofAccess Pharmaceuticals, Inc., +1-214-905-5100; or investor relations,Donald C. Weinberger, or media, Alisa Steinberg, both of Wolfe AxelrodWeinberger Assoc. LLC, +1-212-370-4500; or Andrew Hellman of CEOcast, Inc.,+1-212-732-4300, all for Access Pharmaceuticals, Inc.
Web site: http://www.accesspharma.com/
